{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:15:17Z","timestamp":1788138917566,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271830"],"award-info":[{"award-number":["82271830"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32441095"],"award-info":[{"award-number":["32441095"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical and Health Science Program of Zhejiang Province","award":["2025KY1886"],"award-info":[{"award-number":["2025KY1886"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08467-6","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T08:11:16Z","timestamp":1781770276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular characterisation of telitacicept response phenotypes in systemic lupus erythematosus: an exploratory integrated transcriptome and B-cell receptor repertoire profiling study"],"prefix":"10.1186","volume":"24","author":[{"given":"Mengjie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2044-5424","authenticated-orcid":false,"given":"Yuanjia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"17","key":"8467_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel CH, Sammaritano LR. Systemic Lupus Erythematosus: A Review. JAMA. 2024;331(17):1480\u201391. https:\/\/doi.org\/10.1001\/jama.2024.2315.","journal-title":"JAMA"},{"issue":"1","key":"8467_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molmed.2025.06.003","volume":"32","author":"EF Morand","year":"2026","unstructured":"Morand EF, Jones SA. 10 years in lupus - progress, but not enough. Trends Mol Med. 2026;32(1):11\u2013. https:\/\/doi.org\/10.1016\/j.molmed.2025.06.003. \u20098.","journal-title":"Trends Mol Med"},{"issue":"1","key":"8467_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","volume":"10","author":"X Dai","year":"2025","unstructured":"Dai X, Fan Y, Zhao X. Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics. Signal Transduct Target Ther. 2025;10(1):102. https:\/\/doi.org\/10.1038\/s41392-025-02168-0.","journal-title":"Signal Transduct Target Ther"},{"issue":"14","key":"8467_CR4","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S, Telitacicept. First Approval Drugs. 2021;81(14):1671\u20135. https:\/\/doi.org\/10.1007\/s40265-021-01591-1.","journal-title":"First Approval Drugs"},{"issue":"15","key":"8467_CR5","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","volume":"393","author":"RF van Vollenhoven","year":"2025","unstructured":"van Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F, et al. A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus. N Engl J Med. 2025;393(15):1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2414719.","journal-title":"N Engl J Med"},{"issue":"4","key":"8467_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83(4):475\u201387. https:\/\/doi.org\/10.1136\/ard-2023-224854.","journal-title":"Ann Rheum Dis"},{"key":"8467_CR7","doi-asserted-by":"publisher","unstructured":"Ji L, Geng Y, Zhang X, Deng X, Song Z, Tan M, et al. B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept. MedComm (2020). 2024;5(4):e515. https:\/\/doi.org\/10.1002\/mco2.515","DOI":"10.1002\/mco2.515"},{"key":"8467_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03724-3","author":"Y Wei","year":"2026","unstructured":"Wei Y, Shao Y, Wang X, Qiao L, Wu D, Yang Y, et al. A BAFF\/APRIL dual inhibitor for the treatment of systemic lupus erythematosus: a long-term, observational, real-world study. Arthritis Res Ther. 2026. https:\/\/doi.org\/10.1186\/s13075-025-03724-3.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"8467_CR9","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214819.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8467_CR10","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288\u201391.","journal-title":"J Rheumatol"},{"key":"8467_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-3-319-78999-6_4","volume-title":"Handbook of Mathematical Geosciences: Fifty Years of IAMG","author":"JJ Egozcue","year":"2018","unstructured":"Egozcue JJ, Pawlowsky-Glahn V. Modelling Compositional Data. The Sample Space Approach. In: Daya Sagar BS, Cheng Q, Agterberg F, editors. Handbook of Mathematical Geosciences: Fifty Years of IAMG. Cham: Springer International Publishing; 2018. pp. 81\u2013103."},{"issue":"5","key":"8467_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337.","journal-title":"Nat Methods"},{"key":"8467_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.coi.2021.05.011","volume":"71","author":"E McAllister","year":"2021","unstructured":"McAllister E, Jellusova J. BAFF signaling in B cell metabolism. Curr Opin Immunol. 2021;71:69\u201374. https:\/\/doi.org\/10.1016\/j.coi.2021.05.011.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"8467_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","volume":"10","author":"FB Vincent","year":"2014","unstructured":"Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF\/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365\u201373. https:\/\/doi.org\/10.1038\/nrrheum.2014.33.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"8467_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/ard-2023-224795","volume":"83","author":"I Parodis","year":"2024","unstructured":"Parodis I, Lindblom J, Barturen G, Ortega-Castro R, Cervera R, Pers JO, et al. Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort. Ann Rheum Dis. 2024;83(7):889\u2013900. https:\/\/doi.org\/10.1136\/ard-2023-224795.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8467_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13075-025-03584-x","volume":"27","author":"X Chen","year":"2025","unstructured":"Chen X, Hu L, Zhu L, Tu J, Gui J, Fang M, et al. Prospective analysis of B cell subset dynamics following telitacicept treatment in systemic lupus erythematosus. Arthritis Res Ther. 2025;27(1):126. https:\/\/doi.org\/10.1186\/s13075-025-03584-x.","journal-title":"Arthritis Res Ther"},{"key":"8467_CR17","doi-asserted-by":"publisher","unstructured":"Zhang Y, Lee TY. Revealing the immune heterogeneity between systemic lupus erythematosus and rheumatoid arthritis based on multi-omics data analysis. Int J Mol Sci. 2022;23(9). https:\/\/doi.org\/10.3390\/ijms23095166.","DOI":"10.3390\/ijms23095166"},{"issue":"11","key":"8467_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1136\/ard-2023-224421","volume":"82","author":"M Ota","year":"2023","unstructured":"Ota M, Nakano M, Nagafuchi Y, Kobayashi S, Hatano H, Yoshida R, et al. Multimodal repertoire analysis unveils B cell biology in immune-mediated diseases. Ann Rheum Dis. 2023;82(11):1455\u201363. https:\/\/doi.org\/10.1136\/ard-2023-224421.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8467_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.42750","volume":"76","author":"C Dong","year":"2024","unstructured":"Dong C, Guo Y, Chen Z, Li T, Ji J, Sun C, et al. Single-Cell Profiling of Bone Marrow B Cells and Early B Cell Developmental Disorders Associated With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2024;76(4):599\u2013613. https:\/\/doi.org\/10.1002\/art.42750.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"8467_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s12016-024-08984-6","volume":"66","author":"Q Wang","year":"2024","unstructured":"Wang Q, Feng D, Jia S, Lu Q, Zhao M, B-Cell Receptor. Repertoire: Recent Advances in Autoimmune Diseases. Clin Rev Allergy Immunol. 2024;66(1):76\u201398. https:\/\/doi.org\/10.1007\/s12016-024-08984-6.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7776","key":"8467_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41586-019-1595-3","volume":"574","author":"RJM Bashford-Rogers","year":"2019","unstructured":"Bashford-Rogers RJM, Bergamaschi L, McKinney EF, Pombal DC, Mescia F, Lee JC, et al. Analysis of the B cell receptor repertoire in six immune-mediated diseases. Nature. 2019;574(7776):122\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1595-3.","journal-title":"Nature"},{"issue":"12","key":"8467_CR22","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1093\/rheumatology\/keaf386","volume":"64","author":"TS Ushijima","year":"2025","unstructured":"Ushijima TS, Teruya H, Abe T, Itamiya T, Ota M, Okamura T, et al. Stratification of systemic lupus erythematosus with IGHV4-34 in unswitched memory B cells. Rheumatology (Oxford). 2025;64(12):6099\u2013105. https:\/\/doi.org\/10.1093\/rheumatology\/keaf386.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"8467_CR23","doi-asserted-by":"publisher","first-page":"e000270","DOI":"10.1136\/lupus-2018-000270","volume":"6","author":"L R\u00f6nnblom","year":"2019","unstructured":"R\u00f6nnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1):e000270. https:\/\/doi.org\/10.1136\/lupus-2018-000270.","journal-title":"Lupus Sci Med"},{"issue":"8","key":"8467_CR24","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.immuni.2024.05.025","volume":"57","author":"H Xu","year":"2024","unstructured":"Xu H, Zhang X, Wang X, Li B, Yu H, Quan Y, et al. Cellular spermine targets JAK signaling to restrain cytokine-mediated autoimmunity. Immunity. 2024;57(8):1796\u2013811. https:\/\/doi.org\/10.1016\/j.immuni.2024.05.025. e8.","journal-title":"Immunity"},{"issue":"4","key":"8467_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1101\/gr.265249.120","volume":"31","author":"B Panwar","year":"2021","unstructured":"Panwar B, Schmiedel BJ, Liang S, White B, Rodriguez E, Kalunian K, et al. Multi-cell type gene coexpression network analysis reveals coordinated interferon response and cross-cell type correlations in systemic lupus erythematosus. Genome Res. 2021;31(4):659\u201376. https:\/\/doi.org\/10.1101\/gr.265249.120.","journal-title":"Genome Res"},{"issue":"1","key":"8467_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/imr.12810","volume":"292","author":"SW Jackson","year":"2019","unstructured":"Jackson SW, Davidson A. BAFF inhibition in SLE-Is tolerance restored? Immunol Rev. 2019;292(1):102\u201319. https:\/\/doi.org\/10.1111\/imr.12810.","journal-title":"Immunol Rev"},{"key":"8467_CR27","doi-asserted-by":"publisher","first-page":"105704","DOI":"10.1016\/j.ejps.2021.105704","volume":"159","author":"X Yao","year":"2021","unstructured":"Yao X, Ren Y, Zhao Q, Chen X, Jiang J, Liu D, et al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS\/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci. 2021;159:105704. https:\/\/doi.org\/10.1016\/j.ejps.2021.105704.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"8467_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41577-024-01112-7","volume":"25","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Zhang C. Regulation of cGAS-STING signalling and its diversity of cellular outcomes. Nat Rev Immunol. 2025;25(6):425\u201344. https:\/\/doi.org\/10.1038\/s41577-024-01112-7.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"8467_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.immuni.2024.03.004","volume":"57","author":"T Kawai","year":"2024","unstructured":"Kawai T, Ikegawa M, Ori D, Akira S. Decoding Toll-like receptors: Recent insights and perspectives in innate immunity. Immunity. 2024;57(4):649\u201373. https:\/\/doi.org\/10.1016\/j.immuni.2024.03.004.","journal-title":"Immunity"},{"issue":"1","key":"8467_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8(1):204. https:\/\/doi.org\/10.1038\/s41392-023-01468-7.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08467-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08467-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08467-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:46:34Z","timestamp":1788137194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08467-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8467"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08467-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. The study was approved by the Ethics Committee of First People\u2019s Hospital of Wenling (Ethics approval number: KY-2024-1112-01). All study participants gave written informed consent and were informed about the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1113"}}